The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer.
Joseph B. Babigumira
Consultant or Advisory Role - Genentech
Eduardo Santos
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Vincent Percival Antao
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Bruce Wang
Consultant or Advisory Role - Genentech
Chia C. Portera
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Tripthi Kamath
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Louis P Garrison
Consultant or Advisory Role - Genentech